| Market Cap | 684M | P/E | - | EPS this Y | 27.80% | Ern Qtrly Grth | - |
| Income | -279.42M | Forward P/E | -2.01 | EPS next Y | 2.60% | 50D Avg Chg | -10.00% |
| Sales | 65k | PEG | -1.80 | EPS past 5Y | - | 200D Avg Chg | -30.00% |
| Dividend | N/A | Price/Book | 1.26 | EPS next 5Y | 1.00% | 52W High Chg | -73.00% |
| Recommedations | 2.00 | Quick Ratio | 11.97 | Shares Outstanding | 209.11M | 52W Low Chg | 9.00% |
| Insider Own | 17.48% | ROA | -23.88% | Shares Float | 152.10M | Beta | 0.83 |
| Inst Own | 80.69% | ROE | -49.11% | Shares Shorted/Prior | 39.19M/39.23M | Price | 4.69 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 2,616,766 | Target Price | 9.59 |
| Oper. Margin | -416,624.60% | Earnings Date | Oct 31 | Volume | 2,684,209 | Change | -2.09% |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| HC Wainwright & Co. | Buy | Aug 15, 24 |
| Citigroup | Buy | Aug 9, 24 |
| Truist Securities | Buy | Aug 9, 24 |
| Canaccord Genuity | Buy | Aug 8, 24 |
| Piper Sandler | Overweight | May 31, 24 |
| Oppenheimer | Outperform | May 21, 24 |
| HC Wainwright & Co. | Buy | May 16, 24 |
| Truist Securities | Buy | May 15, 24 |
| Stifel | Hold | May 14, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mayo Stephen | Director Director | Aug 07 | Sell | 4.2855 | 10,000 | 42,855 | 25,328 | 08/09/23 |
| Bhavnagri Veer | General Counsel General Counsel | Jan 17 | Sell | 7.04 | 3,000 | 21,120 | 580,677 | 01/18/23 |
| WITTE OWEN N. | Director Director | Aug 11 | Sell | 16.88 | 15,000 | 253,200 | 218,271 | 08/15/22 |
| Amado Rafael | EVP of R&D and CMO EVP of R&D and CMO | Aug 02 | Sell | 11.97 | 2,000 | 23,940 | 540,257 | 08/02/22 |
| Amado Rafael | EVP of R&D and CMO EVP of R&D and CMO | Jun 21 | Sell | 11.18 | 2,000 | 22,360 | 544,257 | 06/22/22 |
| Amado Rafael | EVP of R&D and CMO EVP of R&D and CMO | May 19 | Sell | 7.3993 | 11,500 | 85,092 | 546,257 | 05/19/22 |
| Amado Rafael | EVP of R&D and CMO EVP of R&D and CMO | Mar 15 | Sell | 7.7090 | 5,169 | 39,848 | 320,119 | 03/17/22 |
| Bhavnagri Veer | General Counsel General Counsel | Mar 15 | Sell | 7.6802 | 8,849 | 67,962 | 413,841 | 03/17/22 |
| Chang David D | President and CEO President and CEO | Mar 15 | Sell | 7.6488 | 23,648 | 180,879 | 2,289,652 | 03/17/22 |
| SCHMIDT ERIC THOMAS | Chief Financial Offi.. Chief Financial Officer | Mar 15 | Sell | 7.6337 | 11,469 | 87,551 | 100,546 | 03/17/22 |
| MOORE ALISON | Chief Technical Offi.. Chief Technical Officer | Mar 15 | Sell | 7.6326 | 8,698 | 66,388 | 120,430 | 03/17/22 |
| Kazam Joshua A | Director Director | Jan 12 | Buy | 12.60 | 15,000 | 189,000 | 258,885 | 01/14/22 |
| Belldegrun Arie | Director Director | Jan 12 | Buy | 12.60 | 155,039 | 1,953,491 | 195,039 | 01/14/22 |
| SCHMIDT ERIC THOMAS | Chief Financial Offi.. Chief Financial Officer | Jan 19 | Sell | 31.82 | 30,000 | 954,600 | 1,152,595 | 01/19/21 |
| SCHMIDT ERIC THOMAS | Chief Financial Offi.. Chief Financial Officer | Nov 18 | Sell | 32.8 | 15,000 | 492,000 | 1,182,595 | 11/18/20 |
| SCHMIDT ERIC THOMAS | Chief Financial Offi.. Chief Financial Officer | Oct 16 | Sell | 41.24 | 15,000 | 618,600 | 1,197,595 | 10/16/20 |
| MOORE ALISON | Chief Technical Offi.. Chief Technical Officer | Oct 09 | Option | 2.27 | 35,264 | 80,049 | 147,879 | 10/09/20 |
| MOORE ALISON | Chief Technical Offi.. Chief Technical Officer | Oct 09 | Sell | 41 | 44,574 | 1,827,534 | 108,370 | 10/09/20 |
| MOORE ALISON | Chief Technical Offi.. Chief Technical Officer | Oct 08 | Option | 2.27 | 35,264 | 80,049 | 161,536 | 10/08/20 |
| MOORE ALISON | Chief Technical Offi.. Chief Technical Officer | Oct 08 | Sell | 40 | 44,574 | 1,782,960 | 117,680 | 10/08/20 |
| Bhavnagri Veer | General Counsel General Counsel | Oct 08 | Option | 2.27 | 10,000 | 22,700 | 363,902 | 10/08/20 |
| Bhavnagri Veer | General Counsel General Counsel | Oct 08 | Sell | 40 | 10,000 | 400,000 | 353,902 | 10/08/20 |
| SCHMIDT ERIC THOMAS | Chief Financial Offi.. Chief Financial Officer | Sep 22 | Sell | 35.92 | 15,000 | 538,800 | 1,212,595 | 09/22/20 |